Donate

Grifols Launches Higher Potency Alphanate

September 20, 2014

Grifols, a leader in the production of plasma-derived medicines, announces the launch of a 2000 IU/vial assay size for ALPHANATE. ALPHANATE is indicated for the control and prevention of bleeding in patients with Hemophilia A and for surgical and/or invasive procedures in adult and pediatric patients with von Willebrand disease in whom desmopressin (DDAVP) is […]


Sign up for E-mails, Dateline Magazine, and other ways to stay connected.